Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cristiam Moreno Tellez

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Surgical Oncology Clinics of North America|June 17, 2022
Immunotherapy in Sarcoma: Where Do Things Stand?Cristiam Moreno Tellez, Yan Leyfman, Sandra P D'Angelo, et al.
Cancer Research|May 19, 2023
Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response PathwayMichael P Ludwig, Matthew D Galbraith, Neetha Paul Eduthan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2025
A single arm phase 2 trial of doxorubicin plus zalifrelimab (anti-CTLA-4 antibody) and balstilimab (anti-PD-1 antibody) in advanced/metastatic soft tissue sarcomasBreelyn A Wilky, Katherine A Julian, Alessandra Maleddu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2022
Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective StudyMichael J Nathenson, Junxiao Hu, Ravin Ratan, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Surgical Oncology Clinics of North America|June 17, 2022
Immunotherapy in Sarcoma: Where Do Things Stand?Cristiam Moreno Tellez, Yan Leyfman, Sandra P D'Angelo, et al.
Cancer Research|May 19, 2023
Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response PathwayMichael P Ludwig, Matthew D Galbraith, Neetha Paul Eduthan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2025
A single arm phase 2 trial of doxorubicin plus zalifrelimab (anti-CTLA-4 antibody) and balstilimab (anti-PD-1 antibody) in advanced/metastatic soft tissue sarcomasBreelyn A Wilky, Katherine A Julian, Alessandra Maleddu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2022
Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective StudyMichael J Nathenson, Junxiao Hu, Ravin Ratan, et al.
Pageof 1